-
Advancing gender equity to improve kidney care for women: a patient perspective Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-11-19 Annalijn I. Conklin, Sofia B. Ahmed
Women living with kidney disease are exposed to several sex and gender gaps in the clinical practice of standard hemodialysis treatment. Drawing on lived experience, we offer opportunities for improvement and call on nephrology clinicians and researchers to advance gender equity and improve health outcomes for women.
-
Collagen formation, function and role in kidney disease Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-11-15 Vanessa De Gregorio, Moumita Barua, Rachel Lennon
-
PI3Kα in the pathogenesis and treatment of lupus nephritis. Kidney Int. (IF 14.8) Pub Date : 2024-11-16 Vivek Kasinath,George C Tsokos
-
Translational Science Advancing Anti-Inflammatory Therapies - Leveraging Glucocorticoid Pathways for Novel Treatments. Kidney Int. (IF 14.8) Pub Date : 2024-11-16 Valerie Etzrodt,Huihui Huang,Samir M Parikh
-
Post-hoc analysis of the CARES trial suggests delayed progression of chronic kidney disease in patients with gout during urate-lowering therapy. Kidney Int. (IF 14.8) Pub Date : 2024-11-15 Byeongzu Ghang,Jino Park,Ji Sung Lee,Joon Seo Lim,Hyunwoo Kim,David F L Liew,Jinseok Kim,Duk-Hee Kang,Bin Yoo
Based on the hypothesis that hyperuricemia is a modifiable risk factor for chronic kidney disease (CKD) progression, there is an expectation that urate-lowering therapy (ULT) could delay the progression of CKD. Here, we investigated changes in kidney function and the association of the serum uric acid (sUA) level and kidney function during ULT in patients with gout. To do this we conducted post-hoc
-
A randomized controlled trial evaluated the efficacy and safety of apixaban for prevention of recurrent thrombosis after thrombectomy of hemodialysis vascular access. Kidney Int. (IF 14.8) Pub Date : 2024-11-15 Tsung-Yu Ko,Chih-Cheng Wu,Mu-Yang Hsieh,Chung-Wei Yang,Chi-Hung Cheng,Chun-Kai Chen,Hsien-Li Kao
Dialysis vascular access thrombosis poses a substantial challenge for individuals undergoing hemodialysis. The efficacy and safety of apixaban, a direct oral coagulation factor Xa inhibitor, in preventing recurrent access thrombosis have yet to be explored. Here, a multicenter randomized control study (NCT04489849) enrolled hemodialysis patients to evaluate this who underwent successful endovascular
-
Improved Survival in Patients Receiving Hemodialysis Through Changes in Practice Patterns: Does This Apply to Your Country? Am. J. Kidney Dis. (IF 9.4) Pub Date : 2024-11-15 Anneke Kramer,Rianne Boenink,Vianda S Stel
-
Harmonizing the Different Perspectives on Growth Impairment in Pediatric CKD. Am. J. Kidney Dis. (IF 9.4) Pub Date : 2024-11-15 Melissa S Zhou,Alexander J Wolf,Ken Sutha
-
Clinicopathologic, Proteomic and Outcome Characteristics of Renal Apolipoprotein C-II Amyloidosis: A Case Series. Am. J. Kidney Dis. (IF 9.4) Pub Date : 2024-11-13 Samih H Nasr,Surendra Dasari,Anthony M Valeri,Jason D Theis,Ann Moyer,Alessia Buglioni,M Barry Stokes,Linda Hasadsri,Julie A Vrana,Samar M Said,Satoru Kudose,Neeraja Kambham,Mei Lin Bissonnette,Lihong Bu,Renu Gupta,Attaya Suvannasankha,Suzanne Martin,Xu Zeng,Renuka Sothinathan,Adil Jadoon,Tewabe Kebede,Srimathi Manickaratnam,Jordan L Rosenstock,Glen S Markowitz,Sanjeev Sethi,Nelson Leung,Ellen D McPhail
RATIONALE & OBJECTIVE Amyloidosis derived from apolipoprotein C-II (AApoCII) is a recently discovered, rare form of amyloidosis. Data on clinical presentations and natural history are very limited. This study defines the clinicopathologic, proteomic and outcome characteristics of renal AApoCII. STUDY DESIGN Case series. SETTING & PARTICIPANTS Twenty-five renal AApoCII cases were identified from the
-
Lupus nephritis: redefining the treatment goals Kidney Int. (IF 14.8) Pub Date : 2024-11-08 An S. De Vriese, Sanjeev Sethi, Fernando C. Fervenza
The course of proliferative lupus nephritis is characterized by flares of activity alternating with periods of quiescence against a background of chronic immune dysregulation. An accurate assessment of disease activity is of unassailable importance to tailor therapy. In the present communication, we discuss the available clinical, serologic, and histologic tools to evaluate disease activity and how
-
Adamts1 and Cyst Expansion in Polycystic Kidney Disease. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-11-08 Vijayakumar R Kakade,Zafer Akman,Manga Motrapu,Marcelo F Cassini,Leyuan Xu,Gilbert Moeckel,Stefan Somlo,Lloyd G Cantley
BACKGROUND Autosomal dominant polycystic kidney disease (ADPKD) is characterized by mutations in either the Pkd1 or Pkd2 genes leading to progressive cyst growth and often kidney failure. We have previously demonstrated that tubules can enlarge following loss of Pkd1 without an increase in tubular cell numbers, suggesting that tubular basement membrane remodeling is important for cystic dilation. RNA
-
Baseline Diastolic BP and BP-Lowering Effects on Cardiovascular Outcomes and All-Cause Mortality: A Meta Analysis. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-11-08 Amara Sarwal,Robert E Boucher,Sydney E Hartsell,Guo Wei,Jincheng Shen,Glenn M Chertow,Paul K Whelton,Alfred K Cheung,John William McEvoy,Tom Greene,Srinivasan Beddhu
BACKGROUND Lowering blood pressure (BP) in persons with low diastolic BP could be harmful. Hence, we examined whether baseline diastolic BP modifies the effects of BP lowering on clinical outcomes in a meta-analysis of five large BP lowering trials. METHODS In a study-level meta-analysis based on individual participant data of the Systolic Blood Pressure Intervention Trial (N = 9361), the Action to
-
Surrogate Endpoints in APOL1-Associated Kidney Disease: Evaluation in Three Cohorts Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-11-05 Alix Rosenberg, Carina Flaherty, Amanda Anderson, Lawrence J Appel, Josef Coresh, Jiang He, Jim Lash, Celina Liu, Panduranga Rao, Jonathan Taliercio, Aditya Surapaneni, Morgan Grams, on behalf of the CRIC Study Investigators
lysis included African-American participants in the Atherosclerosis Risk in Communities (ARIC) study (N=3071), the Chronic Renal Insufficiency Cohort (CRIC; N=998), and the African American Study of Kidney Disease and Hypertension (AASK; N=609). Surrogate endpoints included three-year 30% and 40% decline in glomerular filtration rate (GFR), doubling of urine protein-to-creatinine ratio (UPCR), and
-
Bisphosphonate Use After Kidney Transplantation Is Associated with Lower Fracture Risk Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-11-05 Joseph M Kahwaji, Su-Jau Yang, John Sim, Chong Young Parke, Roland L. Lee
bisphosphonates associates with lower incidence of non-vertebral fractures after kidney transplantation. Methods: We conducted a retrospective review for all Southern California Kaiser Permanente kidney transplant recipients with osteoporosis transplanted between 2000 and 2019. Baseline variables were collected. Those prescribed an oral bisphosphonate were compared to those who were not. The primary
-
Trends in Kidney Allograft Failure Among First-Time Transplant Recipients in the United States. Am. J. Kidney Dis. (IF 9.4) Pub Date : 2024-11-07 Pascale Khairallah,Elizabeth C Lorenz,Amy Waterman,Nidhi Aggarwal,Akshta Pai,Wolfgang C Winkelmayer,Jingbo Niu
RATIONALE & OBJECTIVE The management and outcomes of kidney transplant recipients have evolved over the past three decades. This study of U.S patients whose first kidney allograft failed sought to understand long-term trends in subsequent waitlisting, re-transplantation, and all-cause mortality. STUDY DESIGN Retrospective cohort study. SETTING & PARTICIPANTS Patients recorded in the United States Renal
-
Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study Am. J. Kidney Dis. (IF 9.4) Pub Date : 2024-11-07 Emilie J. Lambourg PhD, Edouard L. Fu PhD, Stuart McGurnaghan PhD, Bryan R. Conway PhD, Neeraj Dhaun PhD, Christopher H. Grant MPH, Ewan R. Pearson PhD, Patrick B. Mark PhD, John Petrie PhD, Helen Colhoun PhD, Samira Bell MD, Scottish Diabetes Research Network Epidemiology Group, Rory McCrimmon, Catherine Armstrong, Alistair Emslie-Smith, Robert Lindsay, Sandra MacRury, John McKnight, Donald Pearson
Current guidance recommends against the use of metformin in people with advanced kidney impairment despite a lack of supporting evidence. The aim of this observational study was to compare outcomes of patients with type 2 diabetes who continued versus stopped metformin after developing stage 4 chronic kidney disease (CKD) (eGFR <30 ml/min/1.73m2).
-
Vadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD. Am. J. Kidney Dis. (IF 9.4) Pub Date : 2024-11-07 Hakan R Toka,Marializa Bernardo,Steven K Burke,Wenli Luo,Roberto Manllo-Karim,Irfan Ullah,Zhihui Yang,Zhiqun Zhang,James Tumlin
RATIONALE & OBJECTIVE Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) may offer an alternative erythropoiesis-stimulating agents (ESA) for the treatment of anemia in the setting of CKD. To investigate the efficacy and safety of conversion from long-acting erythropoiesis-stimulating agent (ESA) methoxy polyethylene glycol-epoetin beta (MPG-EPO) to the oral hypoxia-inducible factor
-
From Calculations to Care: The Impact of Changes in Kidney Function Estimation on a Patient's Experience of Care. Am. J. Kidney Dis. (IF 9.4) Pub Date : 2024-11-07 Kristine Marie Guevarra Almonte,Gregory D Mumford,Pipier Smith-Mumford,David Lee,Martha Pavlakis,Melanie Hoenig,Aditya S Pawar
-
CJASN: A Prelude to the Future Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-11-07 Connie M. Rhee, on behalf of the CJASN Editorial Team
An abstract is unavailable.
-
Kidney disease and reproductive health Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-11-05 Priscilla A. Smith, Ippokratis Sarris, Katherine Clark, Kate Wiles, Kate Bramham
-
Unlocking the potential of extracellular vesicles in nephrology: what does MISEV2023 add? Kidney Int. (IF 14.8) Pub Date : 2024-11-06 Monica Suet Ying Ng, Dylan Burger, Per Svenningsen, Elena Martens, Uta Erdbrügger, Fabian Braun
Extracellular vesicles, small membrane-bound packages secreted by virtually all cells of the body, have become a focus of interest in nephrology over the recent years. After the first characterization of their proteomic and transcriptomic content, the scientific attention shifted toward their potential as biomarkers for kidney diseases both as diagnostic and monitoring tools. More recently, researchers
-
Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases Kidney Int. (IF 14.8) Pub Date : 2024-11-06 Mark Canney, Mohammad Atiquzzaman, Yuyan Zheng, Dilshani Induruwage, Yinshan Zhao, Lee Er, Christopher B. Fordyce, Sean J. Barbour
Patients with glomerular disease are at high risk of cardiovascular disease but the contribution of immunosuppression to this risk is unclear. In this retrospective cohort study of 1912 patients (comprised of 759 with IgA nephropathy, 540 with focal segmental glomerulosclerosis, 387 with membranous nephropathy and 226 with minimal change disease) from British Columbia, Canada, we evaluated the association
-
The glomerular circadian clock temporally regulates basement membrane dynamics and the podocyte glucocorticoid response Kidney Int. (IF 14.8) Pub Date : 2024-11-06 Rebecca Preston, Ruby Chrisp, Michal Dudek, Mychel P.T. Morais, Pinyuan Tian, Emily Williams, Richard Naylor, Bernard Davenport, Dharshika R.J. Pathiranage, Emma Benson, David Spiller, James Bagnall, Leo Zeef, Craig Lawless, Syed Murtuza-Baker, Qing-Jun Meng, Rachel Lennon
Kidney physiology shows diurnal variation, and a disrupted circadian rhythm is associated with kidney disease. However, it remains largely unknown whether glomeruli, the filtering units in the kidney, are under circadian control. Here, we investigated core circadian clock components in glomeruli, together with their rhythmic targets and modes of regulation. With clock gene reporter mice, cell-autonomous
-
Is IgA Class Switching Epigenetically Wired?: Untangling the Evidence. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-11-05 Ghazal Z Quinn,Katalin Susztak
-
Selective Cytopheretic Device (QUELimmuneTM): A Leukocyte Processing, Immunomodulatory Device. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-11-05 Christopher J Pino,Kimberly A Johnston,Angela J Westover,H David Humes
-
Involving Patients in the Design of Clinical Trials in Nephrology. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-11-05 Andrea K Viecelli,Allison Jaure,Katharine Hegerty,Nicole Scholes-Robertson
-
External Validation of an Electronic Health Record-Based Diagnostic Model for Histological Acute Tubulointerstitial Nephritis. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-11-05 Dennis G Moledina,Kyra Shelton,Steven Menez,Abinet M Aklilu,Yu Yamamoto,Bashar A Kadhim,Melissa Shaw,Candice Kent,Amrita Makhijani,David Hu,Michael Simonov,Kyle O'Connor,Jack Bitzel,Heather Thiessen-Philbrook,F Perry Wilson,Chirag R Parikh
BACKGROUND Accurate diagnosis of acute tubulointerstitial nephritis (AIN) often requires a kidney biopsy. We previously developed a diagnostic statistical model for predicting biopsy-confirmed AIN by combining four laboratory tests after evaluating over 150 potential predictors from the electronic health record. Here, we validate this diagnostic model in two biopsy-based cohorts at Johns Hopkins Hospital
-
Anticoagulation for Patients with Atrial Fibrillation Receiving Dialysis: A Pilot Randomized Controlled Trial. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-11-04 Ziv Harel,Brendan Smyth,Sunil V Badve,Daniel Blum,William Beaubien-Souligny,Samuel A Silver,Edward Clark,Rita Suri,Thomas A Mavrakanas,Joanna Sasal,Bhanu Prasad,John Eikelboom,Karthik Tennankore,Claudio Rigatto,Ivana Prce,Francois Madore,Fabrice Mac-Way,Andrew Steele,Yangmin Zeng,Michelle Sholzberg,Paul Dorian,Andrew T Yan,Manish M Sood,David J Gladstone,Eric Tseng,Abhijat Kitchlu,Michael Walsh,Danny
BACKGROUND Atrial fibrillation is common in individuals receiving dialysis. The role of oral anticoagulation in this population is uncertain given its exclusion from previous seminal clinical trials. Our objective was to determine the feasibility of performing a large definitive trial to establish the optimal anticoagulation strategy in individuals with atrial fibrillation receiving dialysis. METHODS
-
Female sex hormones inversely regulate acute kidney disease susceptibility throughout life. Kidney Int. (IF 14.8) Pub Date : 2024-11-01 Yuichiro Kitai,Naoya Toriu,Takahisa Yoshikawa,Yoshiki Sahara,Sonoko Kinjo,Yoko Shimizu,Yuki Sato,Akiko Oguchi,Ryo Yamada,Makiko Kondo,Eiichiro Uchino,Keisuke Taniguchi,Hiroyuki Arai,Takayoshi Sasako,Hironori Haga,Shingo Fukuma,Naoto Kubota,Takashi Kadowaki,Minoru Takasato,Yasuhiro Murakawa,Motoko Yanagita
While epidemiological and experimental studies have demonstrated kidney-protective effects of estrogen and female sex in adulthood, some epidemiological data showed deterioration of kidney function during puberty when estrogen production increases. However, molecular mechanisms explaining these conflicting phenomena remain unknown. Here, we showed that the pubertal sex hormone surge in female mice
-
Population Health Management and Guideline-Concordant Care in CKD: A Secondary Analysis of K-CHAMP. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-11-01 Melanie R Weltman,Linda-Marie U Lavenburg,Zhuoheng Han,Alaa A Alghwiri,Mitra Mosslemi,Bruce L Rollman,Gary S Fischer,Thomas D Nolin,Jonathan G Yabes,Manisha Jhamb
BACKGROUND Gaps in guideline-concordant care for chronic kidney disease (CKD) lead to poor outcomes. The Kidney Coordinated HeAlth Management Partnership (K-CHAMP) cluster randomized trial tested the effect of a population health management intervention versus usual care on CKD progression and evidence-based care delivery in the primary care setting. METHODS K-CHAMP included adults aged 18-85 years
-
Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-11-01 Vikas S Sridhar,Ayodele Odutayo,Satish Garg,Thomas Danne,Alessandro Doria,Michael Mauer,Michael J Davies,Phillip Banks,Manon Girard,David Z I Cherney
BACKGROUND This analysis evaluated the efficacy and safety of sotagliflozin, a dual SGLT1&2 inhibitor, added to insulin in patients with type 1 diabetes and chronic kidney disease (CKD). METHODS We used data from the 52-week pooled inTandem1&2 trials and the 24-week inTandem3 trial to assess the effects of sotagliflozin (200mg [inTandem 1&2 only] or 400mg daily) versus placebo on glycated hemoglobin
-
Whole Grains, Refined Grains, and Diet Quality in Chronic Kidney Disease. Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-11-01 Susanne Fleig,Martin K Kuhlmann
-
Exercise and Cognition in People with Chronic Kidney Disease. Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-11-01 Nicole Scholes-Robertson
-
Social Determinants of Health in Acute Kidney Injury: Looking Beyond the Hospital Room. Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-11-01 Anna E Williams,Clarissa J Diamantidis
-
Cardiopulmonary Exercise Testing in Patients with Chronic Kidney Disease Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-11-01 Marcelle Tuttle, Mark J. Sarnak
An abstract is unavailable.
-
Cancer Screening among Patients with Kidney Failure Requiring Hemodialysis: Where We Are and Where We Are Going Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-11-01 Deepa Jayaram, Ladan Golestaneh
An abstract is unavailable.
-
Impaired Incretin Homeostasis in Nondiabetic Moderate-to-Severe CKD Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-11-01 Armin Ahmadi, Jorge Gamboa, Jennifer E. Norman, Bamba Enkhmaa, Madelynn Tucker, Brian J. Bennett, Leila R. Zelnick, Sili Fan, Lars F. Berglund, Talat Alp Ikizler, Ian H. de Boer, Bethany P. Cummings, Baback Roshanravan
with insulin response and coincided with persistently greater glucagon levels to oral glucose tolerance testing in CKD.Disruption in the incretin system and glucagon dynamics may contribute to metabolic complications in moderate-to-severe CKD. Background Incretins are regulators of insulin secretion and glucose homeostasis metabolized by dipeptidyl peptidase-4 (DPP-4). CKD may modify incretin release
-
ECM remodelling by ADAMTS12 in fibrosis Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-10-30 Susan J. Allison
Fibrosis results from the continuous deposition of extracellular matrix (ECM) by fibroblasts in response to injurious stimuli; however, the exact roles of fibroblasts in this process are unclear. New findings demonstrate a key role for the protease ADAMTS12 in driving fibrosis through the remodelling of ECM and activation of profibrotic fibroblasts. “On the basis of these observations, we hypothesize
-
Beyond Childhood: The Lifelong Kidney Risks for Children with Posterior Urethral Valves. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-31 Elizabeth A K Hunt,Deborah R Stein
-
Long-Term Benefits and Safety of Statins in Patients with Kidney Failure: A Target Trial Emulation Study. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-31 Franco Wing-Tak Cheng,Wanchun Xu,Sydney C W Tang,Eric Yuk-Fai Wan
BACKGROUND Patients with kidney failure are at elevated risk of cardiovascular diseases. Although statins were commonly used to mitigate cardiovascular disease risk among the population with high risk, the evidence for initiating statin therapy among patients with kidney failure remains inconclusive. This study aimed to investigate the long-term benefits and risks associated with statin therapy in
-
Using Simulation to Optimize the Design of Adaptive Clinical Trials. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-31 Cal H Robinson,Rulan S Parekh,Brian H Cuthbertson,Eddy Fan,Yongdong Ouyang,Anna Heath
-
Classification of Predictors of Rapid Development of Kidney Failure and Short-Term Changes in Concentration of Circulating Proteins Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-10-31 Hiroki Kobayashi, Helen C. Looker, Katsuhito Ihara, Zaipul I. Md Dom, Eiichiro Satake, Sok Cin Tye, Kevin L. Duffin, Alessandro Doria, Robert G. Nelson, Andrzej S. Krolewski
ere measured by OLINK proteomics platform at baseline and after a median interval of 3-4 years in 106 individuals with type 1 and 77 with type 2 diabetes in two case-control studies. During 10-year follow-up, 31 and 26 individuals, respectively, developed rapid KF. RESULTS: Deltas for 40 proteins predicted rapid KF in both studies. All were better predictors than delta urine albumin-creatinine ratio
-
Neighborhood Socioeconomic Deprivation is Associated with Worse Outcomes in Pediatric Kidney Transplant Recipients Clin. J. Am. Soc. Nephrol. (IF 8.5) Pub Date : 2024-10-31 Chloe E. Douglas, Miranda C. Bradford, Rachel M Engen, Yue-Harn Ng, Aaron Wightman, Reya Mokiao, Sharon Bartosh, André A S Dick, Jodi M. Smith
listing transplanted January 1st, 2010, to May 31st, 2022 (N=9,178) were included from the Scientific Registry of Transplant Recipients. Recipients were stratified into three groups according to Material Community Deprivation Index score, with greater score representing higher neighborhood socioeconomic deprivation. Outcomes were modeled using multivariable logistic regression and Cox proportional
-
SPRINTing to Conclusions: Evaluating the Long-Term Effects of Intensive BP Control on Kidney Health. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-30 Gregory L Hundemer,Manish M Sood
-
Aiming for a Patient-Centered Organ Procurement and Transplantation Network. Am. J. Kidney Dis. (IF 9.4) Pub Date : 2024-10-30 Sylvia E Rosas,Morgan Reid
-
Long-Term Kidney Outcomes after Pediatric Acute Kidney Injury: Future Studies Need to Explore Further. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-29 Qi Gao,Honglan Wei,Yanqin Li,Licong Su
-
Authors' Reply: Long-Term Kidney Outcomes after Pediatric Acute Kidney Injury: Future Studies Need to Explore Further. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-29 Cal H Robinson,Rahul Chanchlani
-
Exploring the Causal Relationship Between Kidney Function and Cancer Risk: Insights and Limitations of Mendelian Randomization Am. J. Kidney Dis. (IF 9.4) Pub Date : 2024-10-29 Sehoon Park, Jeong Min Cho, Dong Ki Kim
-
Amoxicillin crystalluria and amoxicillin-induced crystal nephropathy: a narrative review Kidney Int. (IF 14.8) Pub Date : 2024-10-28 Dominique Vodovar, Cyril Mousseaux, Michel Daudon, Matthieu Jamme, Emmanuel Letavernier
Amoxicillin crystalluria (AC) refers to the precipitation of amoxicillin in the urine as amoxicillin trihydrate crystals. Amoxicillin-induced crystal nephropathy (AICN) refers to the obstruction of kidney tubules by amoxicillin trihydrate crystals, resulting in acute kidney injury. Usually considered rare and not serious, AC and AICN would be more frequent in patients receiving high-dose i.v. amoxicillin
-
Insights from the BKEVER Trial comparing everolimus versus mycophenolate mofetil for BK Polyomavirus infection in kidney transplant recipients Kidney Int. (IF 14.8) Pub Date : 2024-10-28 Sophie Caillard, Nicolas Meyer, Morgane Solis, Dominique Bertrand, Maite Jaureguy, Dany Anglicheau, Laure Ecotiere, Matthias Buchler, Nicolas Bouvier, Betoul Schvartz, Jean Philippe Rerolle, Anne Elisabeth Heng, Lionel Couzi, Agnes Duveau, Emmanuel Morelon, Yann LeMeur, Léonard Golbin, Eric Thervet, Ilies Benotmane, Samira Fafi-Kremer
The MTOR inhibitors have demonstrated antiviral properties, and prior non-randomized studies have suggested they may have a suppressive effect on BKPyV replication. Here, in this randomized, multicenter, controlled trial (BKEVER study), we sought to evaluate the impact of everolimus (EVR) in facilitating the clearance of BKPyV compared to simply reducing immunosuppression among kidney transplant recipients
-
Prenatal and preimplantation testing for monogenic kidney disorders Kidney Int. (IF 14.8) Pub Date : 2024-10-28 Nine V.A.M. Knoers
In recent years, advances in genetic sequencing techniques and the analysis of sequencing data have significantly improved our ability to diagnose genetic kidney diseases. Identification of the disease-causing genetic variant(s) is crucial not only for prognostication and personalized management, but also for providing genetic counseling and guiding family planning decisions. It is particularly important
-
Sex dimorphism in kidney health and disease: mechanistic insights and clinical implication Kidney Int. (IF 14.8) Pub Date : 2024-10-28 Stefanie Steiger, Li Li, Annette Bruchfeld, Kate I. Stevens, Sarah M. Moran, Jürgen Floege, Fernando Caravaca-Fontán, Safak Mirioglu, Onno Y.K. Teng, Eleni Frangou, Andreas Kronbichler, Immunonephrology Working Group (IWG) of the European Renal Association (ERA)
Sex is a key variable in the regulation of human physiology and pathology. Many diseases disproportionately affect one sex: autoimmune diseases, such as systemic lupus erythematosus, are more common in women but more severe in men, whereas the incidence of other disorders such as gouty arthritis and malignant cancers is higher in men. Besides the pathophysiology, sex may also influence the efficacy
-
Avoiding arrythmias by personalizing the dialysate concentration: a case for precision medicine in patients on dialysis Kidney Int. (IF 14.8) Pub Date : 2024-10-26 T. Alp Ikizler, Tilman B. Drueke, Jürgen Floege, Germaine Wong
Cardiac arrythmias are common in patients undergoing maintenance hemodialysis. In this issue, Charytan et al. showed that in patients with hyperkalemia (serum potassium concentration 5.1–6.5 mEq/l) on hemodialysis, a dialysate concentration of 3 mEq/l combined with sodium zirconium cyclosilicate on dialysis-free days is associated with a low frequency of atrial fibrillation compared with a dialysate
-
Effects of dialysate potassium concentration of 3.0mEq/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0mEq/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia Kidney Int. (IF 14.8) Pub Date : 2024-10-26 David M. Charytan, Wolfgang C. Winkelmayer, Christopher B. Granger, John P. Middleton, Charles A. Herzog, Glenn M. Chertow, James M. Eudicone, Jeremy D. Whitson, James A. Tumlin, ADAPT Investigators
The optimal approach towards managing serum potassium and hemodialysate potassium concentrations is uncertain. To study this, adults receiving hemodialysis for three months or more with hyperkalemia (pre-dialysis serum potassium (sK+) 5.1–6.5 mEq/l) had cardiac monitors implanted and were randomized to either eight weeks of 2.0 potassium/2.5 calcium mEq/l dialysate without sodium zirconium cyclosilicate
-
From Despair to Promise: The Dawn of Novel Treatment in IgA Nephropathy. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-26 Sydney C W Tang,Girish N Nadkarni
-
The Selective Endothelin Receptor Antagonist SC0062 in IgA Nephropathy: A Randomized Double-Blind Placebo-Controlled Clinical Trial. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-26 Hiddo J L Heerspink,Xiaoying Du,Yan Xu,Yanning Zhang,Bin Liu,Guangyu Bi,Chengyun Xu,Qun Luo,Henglan Wu,Jianxin Wan,Liou Cao,Rong Wang,Qiuling Fan,Hong Cheng,Lixia Xu,Jiyi Huang,Aimin Zhong,Qingfeng Peng,Yongjiang Hei,Yiwei Wang,Bo Zhou,Liqin Zhang,Jianghua Chen
-
Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-26 Jonathan Barratt,Sean J Barbour,Robert M Brenner,Kerry Cooper,Xuelian Wei,Necmi Eren,Jürgen Floege,Vivekanand Jha,Sung Gyun Kim,Bart Maes,Richard K S Phoon,Harmeet Singh,Vladimír Tesař,Richard Lafayette,
-
Higher intraoperative blood pressure does not reduce acute kidney injury in noncardiac surgery: what do the results of the POISE-3 trial tell us? Kidney Int. (IF 14.8) Pub Date : 2024-10-25 Nicholas M. Selby, Lui G. Forni
Hypotension is a common cause of acute kidney injury (AKI), with strong associations between the duration and magnitude of hypotension seen across a range of situations including major surgery. However, it is less clear whether targeting higher intraoperative MAP results in lower rates of AKI. In a prespecified analysis of the Perioperative Ischemic Evaluation-3 (POISE-3) randomized controlled trial
-
A sub-study of the POISE-3 randomized trial examined effects of a perioperative hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of acute kidney injury Kidney Int. (IF 14.8) Pub Date : 2024-10-25 POISE-3 Trial Investigators and Study Groups, Amit X. Garg, Maura Marcucci, Meaghan S. Cuerden, Jessica M. Sontrop, Thomas W. Painter, Vladimir Lomivorotov, Daniel I. Sessler, Matthew T.V. Chan, Flavia K. Borges, Kate Leslie, Emmanuelle Duceppe, Chirag R. Parikh, Pavel Roshanov, María José Martínez-Zapata, Chew Yin Wang, Denis Xavier, Sergey Efremov, Giovanni Landoni, Ydo V. Kleinlugtenbelt, Wojciech
In this pre-specified sub-study of the POISE-3 trial, we examined the effect of a perioperative hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of postoperative acute kidney injury (AKI). Altogether, 7307 patients were included from 110 hospitals in 22 countries. Patients were 45 years and older, had or were at risk of atherosclerotic disease, took at least one antihypertensive
-
In Vitro Simulation of Hemodialysis Reveals Hemodialysis-Associated Pro-Arrhythmic Effects in a Human Cardiomyocyte Model. J. Am. Soc. Nephrol. (IF 10.3) Pub Date : 2024-10-25 Thomas Körtl,Niklas Hankowitz,Laura Stengel,Oliver Pfeuffer,Dominic Riedl,Frank Schweda,Katrin Streckfuß-Bömeke,Samuel Sossalla